CN107082812A - 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 - Google Patents
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 Download PDFInfo
- Publication number
- CN107082812A CN107082812A CN201710197757.8A CN201710197757A CN107082812A CN 107082812 A CN107082812 A CN 107082812A CN 201710197757 A CN201710197757 A CN 201710197757A CN 107082812 A CN107082812 A CN 107082812A
- Authority
- CN
- China
- Prior art keywords
- ser
- leu
- val
- thr
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (17)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710197757.8A CN107082812B (zh) | 2017-03-29 | 2017-03-29 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
PCT/CN2017/079679 WO2018176505A1 (zh) | 2017-03-29 | 2017-04-07 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
US16/496,348 US10815303B2 (en) | 2017-03-29 | 2017-04-07 | Fusion protein for restoring the functions of failing immune cells and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710197757.8A CN107082812B (zh) | 2017-03-29 | 2017-03-29 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107082812A true CN107082812A (zh) | 2017-08-22 |
CN107082812B CN107082812B (zh) | 2018-11-13 |
Family
ID=59614186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710197757.8A Active CN107082812B (zh) | 2017-03-29 | 2017-03-29 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10815303B2 (zh) |
CN (1) | CN107082812B (zh) |
WO (1) | WO2018176505A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108285493A (zh) * | 2018-02-02 | 2018-07-17 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
CN108610422A (zh) * | 2018-03-29 | 2018-10-02 | 中国人民解放军军事科学院军事医学研究院 | 抑制pd-1/pd-l1信号通路的结合分子 |
WO2019042153A1 (zh) * | 2017-09-01 | 2019-03-07 | 四川科伦博泰生物医药股份有限公司 | 重组双特异性抗体 |
CN109503718A (zh) * | 2017-11-14 | 2019-03-22 | 拜西欧斯(北京)生物技术有限公司 | 包含免疫检查点抑制剂的融合物及其制备方法和应用 |
WO2019062642A1 (zh) * | 2017-09-29 | 2019-04-04 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
CN110894241A (zh) * | 2018-09-13 | 2020-03-20 | 中国科学院生物物理研究所 | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 |
CN113164558A (zh) * | 2018-09-28 | 2021-07-23 | 皮埃尔法布雷医药公司 | 用于治疗癌症的新型免疫细胞因子 |
CN113840832A (zh) * | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
CN114341197A (zh) * | 2019-07-08 | 2022-04-12 | 普罗根有限公司 | 新的融合蛋白及其用途 |
CN114426585A (zh) * | 2022-02-15 | 2022-05-03 | 广东香雪干细胞再生医学科技有限公司 | 融合蛋白及其表达细胞株与应用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3661954T3 (pl) | 2017-08-03 | 2022-05-16 | Amgen Inc. | Muteiny interleukiny 21 i sposoby leczenia |
TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗pd-1抗體及治療方法 |
KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CA3227386A1 (en) * | 2021-07-28 | 2023-02-02 | Jianing Huang | Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104334573A (zh) * | 2012-04-30 | 2015-02-04 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101426533A (zh) * | 2005-12-08 | 2009-05-06 | 路易斯维尔大学研究基金会有限公司 | 免疫刺激组合物和方法 |
FR2894982A1 (fr) * | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
IL300733A (en) * | 2010-03-05 | 2023-04-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeting immune modulation |
CN104185681A (zh) * | 2012-02-01 | 2014-12-03 | 卡姆普根有限公司 | C1orf32抗体及其用于治疗癌症的用途 |
AU2013278843A1 (en) * | 2012-06-21 | 2014-03-27 | Compugen Ltd. | LSR antibodies, and uses thereof for treatment of cancer |
CN103768596B (zh) * | 2012-10-17 | 2016-06-22 | 苏州丁孚靶点生物技术有限公司 | 用于肿瘤治疗的组合产品、其用途及相关方法 |
CN103965361B (zh) | 2013-02-06 | 2018-10-30 | 上海细胞治疗工程技术研究中心集团有限公司 | 一种t细胞信号的嵌合分子转换器及其用途 |
LT2961831T (lt) | 2013-02-26 | 2020-11-10 | Memorial Sloan Kettering Cancer Center | Kompozicijos ir būdai, skirti imunoterapijai |
PT3702373T (pt) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
US20150273033A1 (en) * | 2013-11-05 | 2015-10-01 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
US10407502B2 (en) * | 2014-01-15 | 2019-09-10 | Kadmon Corporation, Llc | Immunomodulatory agents |
JP6447933B2 (ja) * | 2014-02-21 | 2019-01-09 | アイビーシー ファーマスーティカルズ,インコーポレイテッド | Trop−2発現細胞に対する免疫応答を誘発することによる疾患治療 |
SG11201700978SA (en) * | 2014-08-19 | 2017-03-30 | Univ Okayama Nat Univ Corp | Method for enhancing immune cell function and method for assessing immune cell multifunctionality |
WO2016141387A1 (en) * | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
CN110392692B (zh) * | 2017-04-03 | 2023-07-21 | 豪夫迈·罗氏有限公司 | 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物 |
-
2017
- 2017-03-29 CN CN201710197757.8A patent/CN107082812B/zh active Active
- 2017-04-07 US US16/496,348 patent/US10815303B2/en active Active
- 2017-04-07 WO PCT/CN2017/079679 patent/WO2018176505A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104334573A (zh) * | 2012-04-30 | 2015-02-04 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
Non-Patent Citations (2)
Title |
---|
GENBANK: "GenBank 5WT9_L", 《GENBANK》 * |
GENBANK: "GenBank AAH66254", 《GENBANK》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11421029B2 (en) | 2017-09-01 | 2022-08-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recombinant bispecific antibodies to PD-L1 and CTLA-4 |
WO2019042153A1 (zh) * | 2017-09-01 | 2019-03-07 | 四川科伦博泰生物医药股份有限公司 | 重组双特异性抗体 |
WO2019062642A1 (zh) * | 2017-09-29 | 2019-04-04 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
CN109503718A (zh) * | 2017-11-14 | 2019-03-22 | 拜西欧斯(北京)生物技术有限公司 | 包含免疫检查点抑制剂的融合物及其制备方法和应用 |
CN108285493B (zh) * | 2018-02-02 | 2020-09-15 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
CN108285493A (zh) * | 2018-02-02 | 2018-07-17 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
CN108610422A (zh) * | 2018-03-29 | 2018-10-02 | 中国人民解放军军事科学院军事医学研究院 | 抑制pd-1/pd-l1信号通路的结合分子 |
CN113840832A (zh) * | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
CN110894241A (zh) * | 2018-09-13 | 2020-03-20 | 中国科学院生物物理研究所 | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 |
CN110894241B (zh) * | 2018-09-13 | 2022-01-18 | 中国科学院生物物理研究所 | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 |
CN113164558A (zh) * | 2018-09-28 | 2021-07-23 | 皮埃尔法布雷医药公司 | 用于治疗癌症的新型免疫细胞因子 |
CN114341197A (zh) * | 2019-07-08 | 2022-04-12 | 普罗根有限公司 | 新的融合蛋白及其用途 |
CN114426585A (zh) * | 2022-02-15 | 2022-05-03 | 广东香雪干细胞再生医学科技有限公司 | 融合蛋白及其表达细胞株与应用 |
CN114426585B (zh) * | 2022-02-15 | 2023-10-03 | 广东香雪干细胞再生医学科技有限公司 | 融合蛋白及其表达细胞株与应用 |
Also Published As
Publication number | Publication date |
---|---|
US20200040080A1 (en) | 2020-02-06 |
US10815303B2 (en) | 2020-10-27 |
WO2018176505A1 (zh) | 2018-10-04 |
CN107082812B (zh) | 2018-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107082812B (zh) | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 | |
AU646881B2 (en) | Adoptive immunotherapy with interleukin-7 | |
PT2288372E (pt) | Um mutante de il-2 para o tratamento ou profilaxia de uma doença autoimune | |
CN104231068A (zh) | 人白细胞介素ii突变体及其应用 | |
CN110050062A (zh) | 表达il12的溶瘤弹状病毒 | |
CN109666074B (zh) | 一种趋化因子受体cxcr5的用途 | |
CN101361969A (zh) | 一种治疗性乙肝疫苗及其制备方法和用途 | |
CN1948333B (zh) | 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用 | |
Zheng et al. | Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models | |
CN108384795A (zh) | 作用于tme免疫效应细胞的人工合成基因及验证方法和应用 | |
CN106244540A (zh) | 一种提高cik细胞增殖率和杀伤力的细胞培养方法 | |
CN109280087A (zh) | 一种双靶向转换受体、编码基因、重组表达载体、抗肿瘤nk细胞及其制备方法、应用 | |
CN108285493A (zh) | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 | |
CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
CN103232543B (zh) | 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用 | |
CN105968189A (zh) | B/t淋巴细胞弱化因子免疫原多肽及其用途 | |
SA92120509B1 (ar) | تآزر وتضافر (tnf) مع il-4 | |
CN105705164A (zh) | 用于癌症治疗的免疫刺激性hiv tat衍生多肽 | |
KR20200097654A (ko) | 암 치료를 위한 t 세포의 활성화 방법 | |
CN114773474B (zh) | Nk细胞的制备方法及其抗癌的应用 | |
CN114957441B (zh) | 转基因nk细胞及其在抗肿瘤药物中的应用 | |
CN112010944B (zh) | 一种肽及体外扩增cik细胞的方法 | |
CN101074266A (zh) | 转导肽-人源粒细胞集落刺激因子融合蛋白及其药物组合物 | |
CN109536453B (zh) | 一种免疫细胞及其制备方法和应用 | |
Kehry et al. | Targeting PD-1, TIM-3 and LAG-3 in combination for improved immunotherapy combinations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A fusion protein for restoring the function of depleted immune cells and its application Effective date of registration: 20211208 Granted publication date: 20181113 Pledgee: Industrial Bank Co.,Ltd. Shanghai Luwan sub branch Pledgor: SHANGHAI BIOMED-UNION Co.,Ltd. Registration number: Y2021310000118 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230215 Granted publication date: 20181113 Pledgee: Industrial Bank Co.,Ltd. Shanghai Luwan sub branch Pledgor: SHANGHAI BIOMED-UNION Co.,Ltd. Registration number: Y2021310000118 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230412 Address after: Room 302, Building 1, Zhebei Life and Health Small and Micro Park, Yuedu Middle Road, Dipu Street, Anji County, Huzhou City, Zhejiang Province, 313399 (self declared) Patentee after: Keyi (Zhejiang) Pharmaceutical Technology Co.,Ltd. Address before: 201321 floor 3, building 1, No. 400, Fangchun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Patentee before: SHANGHAI BIOMED-UNION Co.,Ltd. |
|
TR01 | Transfer of patent right |